Literature DB >> 2916660

Renal microvascular effects of vasopressin and vasopressin antagonists.

R M Edwards1, W Trizna, L B Kinter.   

Abstract

The effects of vasopressin (AVP) and vasopressin antagonists on lumen diameters of cortical afferent and efferent arterioles isolated from rabbit kidneys were examined. Over a concentration range of 10(-14) to 10(-7) M, AVP had no effect on lumen diameters of afferent arterioles, although the arterioles were responsive to norepinephrine. Similarly, addition of 10(-8) M AVP to the lumen of afferent arterioles or to the bath of arterioles pretreated with indomethacin had no effect. In contrast, AVP caused a concentration-dependent reduction of lumen diameters of efferent arterioles. AVP was approximately 100-fold more potent than norepinephrine in producing contraction of efferent arterioles. The V1-selective antagonist, [d(CH2)5Tyr(Me)]AVP, and the V1/V2-antagonist, d(CH2)5D-Tyr(Et) desGlyVAVP, inhibited the vasoconstriction produced by AVP in a concentration-dependent but noncompetitive manner. The V2-selective antagonist, [d(CH2)5D-Ile]VAVP, had no significant effect on AVP-induced vasoconstriction. We conclude that, under the in vitro conditions used, AVP selectively contracts efferent arterioles. The results provide direct evidence for a postglomerular vascular effect of AVP in the renal cortex. This activity, together with its previously described effects on the glomerulus, suggests that AVP may produce changes in glomerular function and/or peritubular forces that are involved in tubular reabsorption.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2916660     DOI: 10.1152/ajprenal.1989.256.2.F274

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  40 in total

1.  Effect of remifentanil during cardiopulmonary bypass on incidence of acute kidney injury after cardiac surgery.

Authors:  Wataru Sakai; Yusuke Yoshikawa; Naoyuki Hirata; Michiaki Yamakage
Journal:  J Anesth       Date:  2017-10-30       Impact factor: 2.078

Review 2.  AKI associated with cardiac surgery.

Authors:  Robert H Thiele; James M Isbell; Mitchell H Rosner
Journal:  Clin J Am Soc Nephrol       Date:  2014-11-06       Impact factor: 8.237

3.  Did the beneficial renal outcomes with vasopressin VANISH?

Authors:  Gretchen L Sacha; Simon W Lam; Seth R Bauer
Journal:  Ann Transl Med       Date:  2016-10

4.  Effect of Low-Dose Supplementation of Arginine Vasopressin on Need for Blood Product Transfusions in Patients With Trauma and Hemorrhagic Shock: A Randomized Clinical Trial.

Authors:  Carrie A Sims; Daniel Holena; Patrick Kim; Jose Pascual; Brian Smith; Neils Martin; Mark Seamon; Adam Shiroff; Shariq Raza; Lewis Kaplan; Elena Grill; Nicole Zimmerman; Christopher Mason; Benjamin Abella; Patrick Reilly
Journal:  JAMA Surg       Date:  2019-11-01       Impact factor: 14.766

5.  Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial.

Authors:  François Lauzier; Bruno Lévy; Patrice Lamarre; Olivier Lesur
Journal:  Intensive Care Med       Date:  2006-09-22       Impact factor: 17.440

6.  Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study.

Authors:  Andrea Morelli; Christian Ertmer; Sebastian Rehberg; Matthias Lange; Alessandra Orecchioni; Valeria Cecchini; Alessandra Bachetoni; Mariadomenica D'Alessandro; Hugo Van Aken; Paolo Pietropaoli; Martin Westphal
Journal:  Crit Care       Date:  2009-08-10       Impact factor: 9.097

Review 7.  Role of vasopressin in the management of septic shock.

Authors:  Gökhan M Mutlu; Phillip Factor
Journal:  Intensive Care Med       Date:  2004-04-21       Impact factor: 17.440

8.  Clinical impact of vasopressin infusion on hemodynamics, liver and renal function in pediatric patients.

Authors:  Nameet Jerath; Helena Frndova; Brian W McCrindle; Rebecca Gurofsky; Tilman Humpl
Journal:  Intensive Care Med       Date:  2008-03-19       Impact factor: 17.440

9.  Effects of terlipressin on systemic and regional haemodynamics in catecholamine-treated hyperkinetic septic shock.

Authors:  Andrea Morelli; Monica Rocco; Giorgio Conti; Alessandra Orecchioni; Andrea De Gaetano; Giuliana Cortese; Flaminia Coluzzi; Enrico Vernaglione; Paolo Pelaia; Paolo Pietropaoli
Journal:  Intensive Care Med       Date:  2003-12-12       Impact factor: 17.440

10.  Terlipressin as a rescue therapy for catecholamine-resistant septic shock in children.

Authors:  Dincer Yildizdas; Hacer Yapicioglu; Umit Celik; Yasar Sertdemir; Emre Alhan
Journal:  Intensive Care Med       Date:  2007-12-19       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.